MapLight Therapeutics secured a $372.5 million Series D funding round to fuel development of its pipeline candidates for CNS disorders, including schizophrenia and Alzheimer's disease. The financing marks the third-largest private biotech raise in 2025. MapLight aims to expedite phase 2 trials for its lead schizophrenia drug and expand research across neurodegenerative conditions. The investment underscores investor appetite for novel CNS treatments amid ongoing challenges in psychiatric drug development.